Thromboelastometry versus free-oscillation rheometry and enoxaparin versus tinzaparin: an in-vitro study comparing two viscoelastic haemostatic tests’ dose-responses to two low molecular weight heparins at the time of withdrawing epidural catheters from ten patients after major surgery

BMC Anesthesiology

Owain Thomas¹  Anna Larsson²  Nahreen Tynngård⁴  Ulf Schött³ 

[1] Department of Paediatric Anaesthesia and Intensive Care, SUS Lund University Hospital, Lund, Sweden

[2] Medical Faculty, University of Lund, Lund, Sweden

[3] Department of Anaesthesia and Intensive Care, SUS Lund University Hospital, Lund, Sweden

[4] Department of Clinical Chemistry, Department of Clinical Experimental Medicine, Linköping University, Linköping, Sweden

关键词: Spinal haematoma;    Epidural haematoma;    Tinzaparin;    Enoxaparin;    Postoperative;    Low molecular weight heparin;    Free-oscillation rheometry;    Thromboelastometry;    Factor Xa;    Coagulation;   

Others  :  1234059
DOI  :  10.1186/s12871-015-0145-2

 received in 2015-05-25, accepted in 2015-11-11,  发布年份 2015

【 摘 要 】

Background

Monitoring low molecular weight heparins (LMWH’s) in the perioperative period is prudent in patients at high risk of coagulative complications, especially when the patient has an epidural catheter requiring withdrawal, which is associated with the risk of spinal haematoma. The aim of this study was to evaluate the in vitro dose-responses of two different LMWH’s on two different viscoelastic haemostatic tests, using blood sampled from patients with normal routine coagulation parameters, on the day after major surgery when their epidural catheters were due to be withdrawn.

Methods

Enoxaparin or tinzaparin were added in vitro to blood from ten patients who had undergone oesophageal resection, to obtain plasma concentrations of approximately 0, 0.5, 1.0 and 1.5 IU/mL. Coagulation was monitored using thromboelastometry (ROTEM®) using the InTEM® activating reagent; and free oscillation rheometry (FOR: ReoRox®), activated using thromboplastin. Clot initiation was measured using ROTEM-CT, ReoRox-COT1 and ReoRox–COT2. Clot propagation was measured using ROTEM-CFT, ROTEM-Alpha Angle and ReoRox-Slope. Clot stability was measured using ROTEM-MCF and ReoRox-G’max, and clot lysis was measured using ROTEM-ML and ReoRox-ClotSR.

Results

Clot initiation time assessed by thromboelastometry and FOR was prolonged by increasing concentrations of both LMWH’s (P < 0.01). Equivalent doses of tinzaparin in international units (anti-FXa units) per millilitre prolonged clot initiation more than enoxaparin (P < 0.05). There was significant inter-individual variation – the ranges of CT and COT1 at LMWH-concentrations of 0 and 1.5 IU/mL overlapped. None of the tests reflecting clot formation rate or stability showed a dose–response to either LMWH but clot lysis showed a tentative negative dose–response to the LMWH’s.

Conclusions

Clot initiation time’s dose-dependent prolongation by LMWH’s in this study agrees with previous research, as does tinzaparin’s stronger anti-coagulative effect than enoxaparin at equivalent levels of anti-FXa activity. This casts doubt on the validity of using anti-FXa assays alone to guide dosage of LMWH’s. The significant inter-individual variation in dose–response suggests that the relationship between dose and effect in the postoperative period is complicated. While both ROTEM and FOR may have some role in postoperative monitoring, more research is needed before any conclusion can be made about their clinical usefulness.

【 授权许可】

   
2015 Thomas et al.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

【 参考文献 】

• [1]Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R et al.. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001; 119(1 Suppl):64S-94S.
• [2]Nourbakhsh E, Anvari R, Nugent K. Abdominal wall hematomas associated with low-molecular-weight heparins: an important complication in older adults. J Am Geriatr Soc. 2011; 59(8):1543-1545.
• [3]Brummer TH, Heikkinen A, Jalkanen J, Fraser J, Makinen J, Tomas E et al.. Pharmaceutical thrombosis prophylaxis, bleeding complications and thromboembolism in a national cohort of hysterectomy for benign disease. Hum Reprod. 2012; 27(6):1628-1636.
• [4]Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3 Suppl):188S-203S.
• [5]Cook DJ, Crowther MA. Thromboprophylaxis in the intensive care unit: focus on medical-surgical patients. Crit Care Med. 2010; 38(2 Suppl):S76-S82.
• [6]Harr JN, Moore EE, Chin TL, Ghasabyan A, Gonzalez E, Wohlauer MV et al.. Postinjury hyperfibrinogenemia compromises efficacy of heparin-based venous thromboembolism prophylaxis. Shock. 2014; 41(1):33-39.
• [7]Miyazaki M, Takasita M, Matsumoto H, Sonoda H, Tsumura H, Torisu T. Spinal epidural hematoma after removal of an epidural catheter: case report and review of the literature. J Spinal Disord Tech. 2005; 18(6):547-551.
• [8]Lim W, Meade M, Lauzier F, Zarychanski R, Mehta S, Lamontagne F et al.. Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients*. Crit Care Med. 2015; 43(2):401-410.
• [9]Merli GJ, Groce JB. Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange. P & T : a peer-reviewed journal for formulary management. 2010; 35(2):95-105.
• [10]White RH, Ginsberg JS. Low-molecular-weight heparins: are they all the same? Br J Haematol. 2003; 121(1):12-20.
• [11]Thomas O, Lybeck E, Strandberg K, Tynngard N, Schott U. Monitoring Low Molecular Weight Heparins at Therapeutic Levels: Dose-Responses of, and Correlations and Differences between aPTT, Anti-Factor Xa and Thrombin Generation Assays. PLoS One. 2015; 10(1):e0116835.
• [12]Nilsson CU, Tynngard N, Reinstrup P, Engstrom M. Monitoring fibrinolysis in whole blood by viscoelastic instruments: a comparison of ROTEM and ReoRox. Scand J Clin Lab Invest. 2013; 73(6):457-465.
• [13]Winstedt D, Tynngard N, Olanders K, Schott U. Free oscillation rheometry monitoring of haemodilution and hypothermia and correction with fibrinogen and factor XIII concentrates. Scand J Trauma Resusc Emerg Med. 2013; 21:9. BioMed Central Full Text
• [14]Van PY, Cho SD, Underwood SJ, Morris MS, Watters JM, Schreiber MA. Thrombelastography versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients. J Trauma. 2009; 66(6):1509-1515.
• [15]Atkinson HM, Mewhort-Buist TA, Berry LR, Chan AK. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin. Thromb Haemost. 2009; 102(1):62-68.
• [16]Schaden E, Schober A, Hacker S, Spiss C, Chiari A, Kozek-Langenecker S. Determination of enoxaparin with rotational thrombelastometry using the prothrombinase-induced clotting time reagent. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2010; 21(3):256-261.
• [17]Duhl AJ, Paidas MJ, Ural SH, Branch W, Casele H, Cox-Gill J et al.. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol. 2007; 197(5):457.
• [18]Cammerer U, Dietrich W, Rampf T, Braun SL, Richter JA. The predictive value of modified computerized thromboelastography and platelet function analysis for postoperative blood loss in routine cardiac surgery. Anesth Analg. 2003; 96(1):51-57.
• [19]Luddington RJ. Thrombelastography/thromboelastometry. Clinical & Laboratory Haematology. 2005; 27(2):81-90.
• [20]Tynngard N, Lindahl T, Ramstrom S, Berlin G. Effects of different blood components on clot retraction analysed by measuring elasticity with a free oscillating rheometer. Platelets. 2006; 17(8):545-554.
• [21]Ganter MT, Hofer CK. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg. 2008; 106(5):1366-1375.
• [22]Liszka-Hackzell JJ, Schott U. Presentation of laboratory and sonoclot variables using principal component analysis: identification of hypo- and hypercoagulation in the HELLP syndrome. J Clin Monit Comput. 2004; 18(4):247-252.
• [23]Tynngard N, Lindahl TL, Ramstrom S, Raf T, Rugarn O, Berlin G. Free oscillation rheometry detects changes in clot properties in pregnancy and thrombocytopenia. Platelets. 2008; 19(5):373-378.
• [24]Alban S, Welzel D, Hemker HC. Pharmacokinetic and pharmacodynamic characterization of a medium-molecular-weight heparin in comparison with UFH and LMWH. Semin Thromb Hemost. 2002; 28(4):369-378.
• [25]Feuring M, Wehling M, Schultz A. Dalteparin dose-dependently increases ROTEM((R)) thrombelastography parameters only at supratherapeutic anti-factor Xa levels: an in vitro study. Clin Exp Pharmacol Physiol. 2011; 38(11):783-786.
• [26]Schott U, Nilsson LG, Broman M, Engstrom M. Monitoring of low molecular weight heparin anticoagulation during haemodialysis with a Sonoclot Analyzer. Perfusion. 2010; 25(4):191-196.
• [27]Mittermayr M, Margreiter J, Velik-Salchner C, Klingler A, Streif W, Fries D et al.. Effects of protamine and heparin can be detected and easily differentiated by modified thrombelastography (Rotem): an in vitro study. Br J Anaesth. 2005; 95(3):310-316.
• [28]Louis SG, Van PY, Riha GM, Barton JS, Kunio NR, Underwood SJ et al.. Thromboelastogram-guided enoxaparin dosing does not confer protection from deep venous thrombosis: a randomized controlled pilot trial. The journal of trauma and acute care surgery. 2014; 76(4):937-942.
• [29]Lison S, Weiss G, Spannagl M, Heindl B. Postoperative changes in procoagulant factors after major surgery. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2011; 22(3):190-196.
• [30]Casutt M, Konrad C, Schuepfer G. Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEM. Anaesthesist. 2012; 61(11):948-953.
• [31]Gerotziafas GT, Chakroun T, Samama MM, Elalamy I. In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile. Thromb Haemost. 2004; 92(6):1296-1302.
• [32]Evans PA, Hawkins K, Lawrence M, Williams RL, Barrow MS, Thirumalai N et al.. Rheometry and associated techniques for blood coagulation studies. Med Eng Phys. 2008; 30(6):671-679.
• [33]Ranby M, Ramstrom S, Svensson PO, Lindahl TL. Clotting time by free oscillation rheometry and visual inspection and a viscoelastic description of the clotting phenomenon. Scand J Clin Lab Invest. 2003; 63(6):397-406.
• [34]Incampo F, Carrieri C, Galasso R, Marino R, Ettorre CP, Semeraro N et al.. Co-administration of low molecular weight heparin enhances the profibrinolytic effect of warfarin through different mechanisms. Thromb Res. 2014; 133(4):634-639.
• [35]Mousa SA, Bozarth J, Barrett JS. Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects. J Clin Pharmacol. 2003; 43(7):727-734.
• [36]Brophy DF, Martin EJ, Best AM, Gehr TW, Carr ME. Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction. Journal of thrombosis and haemostasis : JTH. 2004; 2(8):1299-1304.